186 Background: Obesity is associated with risk of BCR after RP. It has been suggested this may be due to poor surgical technique and greater risk of positive margins. We examined whether obesity predicted the risk of a detectable PSA nadir after RP (as a measure of residual PSA-producing tissue left behind) and if this accounted for the greater risk of BCR in obese men in the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Methods: We identified 1,011 men treated with RP from 2001 to 2010 in SEARCH who had known data for pre-operative BMI and ultrasensitive PSA nadir within 6 months after RP. The association between BMI (<25, 25-29.9, and >30 kg/m2) and PSA nadir (0, 0.01-0.09, 0.10-0.19, and >0.2) was tested using chi-squared and linear regression adjusting for clinical and pathological characteristics. A proportional hazards model was used to test the association between BMI and BCR adjusted for clinical and pathological characteristics and with and without PSA nadir. Results: Higher BMI was associated with higher PSA nadir (chi-squared, p=0.03). On multivariate analysis, obesity (p<0.001) was associated with higher PSA nadir. Among men with a PSA nadir <0.2 ng/ml (i.e. those who did not recur based upon PSA nadir alone), obesity was associated with BCR when not adjusted for PSA nadir (HR 1.85, 95% CI 1.19-2.89, p=0.007). Adjusting for PSA nadir attenuated, but did not eliminate this association (HR 1.65, 95% CI 1.05-2.59, p=0.03). Even among men with an undetectable PSA nadir, obesity remained significantly associated with BCR (HR 3.45, 95% CI 1.41-8.47, p=0.007). Interestingly, among men with a detectable PSA nadir, but <0.2 ng/ml, obesity did not predict BCR with (HR 1.21, 95% CI 0.71-2.07, p=0.49) or without adjustment for PSA nadir (HR 1.41, 95% CI =0.82-2.41, p=0.22). Conclusions: Obese men are more likely to have a higher PSA nadir suggesting technical issues confound an ideal operation in obese men. However, the increased PSA nadir does not completely explain the higher PSA recurrence rates. These data further support the idea that obesity is biologically associated with prostate cancer progression. No significant financial relationships to disclose.
Read full abstract